Report

QuickView: Poised for NDA submission

Lipocine has completed its pivotal Phase III study of LPCN 1021, an oral testosterone (T) replacement therapy based on the proprietary Lip’ral drug delivery platform. Full Phase III safety data are expected in Q215. The 2014 US market for T replacement was 6.5m prescriptions. In addition to LPCN 1021, Lipocine is developing a once-daily dosed T replacement and potentially the first oral medication for the prevention of preterm birth.
Underlying
Lipocine Inc

Lipocine is a pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. The company's key product candidate, TLANDO?, is an oral testosterone replacement therapy. Additional pipeline candidates include LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis, LPCN 1111, an oral testosterone therapy product with the potential for once daily dosing, and LPCN 1107, which has the potential to become an oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch